These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 2645844)
41. The big gap at the FDA. Stipp D Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178 [No Abstract] [Full Text] [Related]
42. The Prescription Drug User Fee Act of 1992: speeding up the drug approval process. Bierut MB Healthspan; 1992 Dec; 9(11):12-4. PubMed ID: 10123552 [No Abstract] [Full Text] [Related]
43. FDA announces reforms of drug review process. Anderson C Nature; 1991 Nov; 354(6350):173. PubMed ID: 1961242 [No Abstract] [Full Text] [Related]
44. Development and approval of vaccines in the United States. Botstein P Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047 [TBL] [Abstract][Full Text] [Related]
46. Approval times for supplemental indications for recombinant proteins. Gosse ME; Nelson TF Nat Biotechnol; 1997 Feb; 15(2):130-4. PubMed ID: 9035135 [No Abstract] [Full Text] [Related]
47. Cephalon adds to clinical disappointment in 1997. Glaser V Nat Biotechnol; 1997 Jun; 15(6):495-6. PubMed ID: 9181559 [No Abstract] [Full Text] [Related]
48. Vision and will: the future of the FDA. Epstein D Oncologist; 2009 Apr; 14(4):317-9. PubMed ID: 19365098 [No Abstract] [Full Text] [Related]
49. Monoclonal antibody successes in the clinic. Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394 [TBL] [Abstract][Full Text] [Related]
50. Knowledge is power: legislative control of drug industry trade secrets. O'Reilly JT Spec Law Dig Health Care (Mon); 1987 May; 8(15):7-31. PubMed ID: 10281981 [No Abstract] [Full Text] [Related]
52. The drug approval process and the FDA. Schmidt AM Conn Med; 1975 Apr; 39(4):237-40. PubMed ID: 1149447 [No Abstract] [Full Text] [Related]
53. [Clinical drug testing in the United States]. Engelbart S Fortschr Med; 1983 Jun; 101(22):1021-2, 1049. PubMed ID: 6347848 [No Abstract] [Full Text] [Related]
54. New clinical trials policy at FDA. Vastag B Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196 [No Abstract] [Full Text] [Related]
55. New office and new leader aim to streamline FDA cancer drug review process. Twombly R J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036 [No Abstract] [Full Text] [Related]
56. FDA announces new procedures to speed drug availability for life-threatening and severely debilitating conditions. Clin Pharm; 1989 Jan; 8(1):4. PubMed ID: 2912661 [No Abstract] [Full Text] [Related]
57. A testing approach based on tiny doses still awaits big results. Coombs A Nat Med; 2008 Aug; 14(8):796. PubMed ID: 18685584 [No Abstract] [Full Text] [Related]
58. Sandoz sues FDA over delay in first biogeneric approval. Fox JL Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046 [No Abstract] [Full Text] [Related]
59. Changing the business of healthcare. Carter K Mod Healthc; 1987 Jul; 17(14):54-6, 58, 60 passim. PubMed ID: 10282788 [No Abstract] [Full Text] [Related]